Bengaluru: Shreehas Tambe has been appointed as the Chief Executive Officer and Managing Director of Biocon Limited, effective April 1, 2026, following approvals from the Nomination & Remuneration Committee and the Board.
As the first CEO of Biocon Limited, Shreehas Tambe will lead the integrated platform spanning biosimilars and generics, strengthening the company’s ability to scale operations and compete in global markets.
Alongside this development, Kedar Upadhye has been appointed as Chief Financial Officer of Biocon Limited.
The appointment of Shreehas Tambe comes as part of a broader leadership transition aligned with the full integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited.
This move creates a simplified and unified corporate structure, positioning the organization to expand its leadership across key therapeutic areas such as diabetes, obesity, oncology, and immunology.
The combined entity will leverage a differentiated portfolio comprising biosimilars, insulins, complex generics, and peptides, including GLP–1 therapies.
Also Read: Persistent Names Hari Abhyankar as EVP to Drive Private Equity Growth and AI Transformation
Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited, said: “Biocon has consistently grown by anticipating patient needs and building ahead of the curve. With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise.
Shreehas has been at the forefront of this transformation, leading several strategic milestones, including the acquisition and integration of the Viatris biosimilars business and the expansion of our global footprint. Under his leadership, Biocon Biologics has emerged as one of the world’s top five biosimilar companies, with an estimated valuation of approximately USD 5.5 billion.
As the first CEO to lead the combined business, Shreehas brings deep scientific expertise, strategic rigor, and a steadfast commitment to advancing affordable healthcare. I am confident he will drive disciplined execution and translate our scale into sustained global leadership.”
She further acknowledged the contributions of Siddharth Mittal, stating: “I would like to thank Siddharth for his tremendous contributions to Biocon. Since joining in 2013, he has served with distinction as Chief Financial Officer and later as CEO & Managing Director, playing a pivotal role in shaping the company’s growth trajectory. He will now transition to another leadership role within the Biocon Group.”
Speaking on his appointment, Shreehas Tambe said: “It is an honor and privilege to lead Biocon at such a pivotal moment, as we bring together our biologics and generics businesses to build a leading global medicines company. Biocon is among the few organizations that have transformed access to life-saving treatments by effectively leveraging science and technology. Our success has been driven by exceptional talent, united by a strong sense of purpose and an unwavering commitment to serving patient needs.
As we expand our portfolio and global presence, my focus will be on strengthening our foundation, consolidating our business, and accelerating sustainable growth. I am deeply grateful to our visionary Chairperson Kiran Mazumdar-Shaw and the Board of Directors for the trust and confidence placed in me and look forward to building on Biocon’s strong legacy to make a meaningful difference for patients worldwide.”
Shreehas Tambe joined Biocon nearly three decades ago as a management trainee and has since played a pivotal role in scaling multiple global businesses within the organization.
During his tenure as CEO and Managing Director of Biocon Biologics Limited, Shreehas Tambe led the company to become one of the world’s top five biosimilar companies by revenue, achieving a valuation of approximately USD 5.5 billion in 2025. He spearheaded the transformational acquisition of the biosimilars business and oversaw its rapid consolidation into a fully integrated, lab-to-patient biosimilars enterprise.
Prior to this, Shreehas Tambe served as Chief Operating Officer and later Deputy CEO of Biocon Biologics, where he drove enterprise-wide operations and global growth. Earlier in his career at Biocon, he led the worldwide expansion of the insulins business, including the development of Asia’s largest integrated insulins facility in Malaysia.
Also Read: Leadership Transition: Cyient Appoints Prabhakar Atla as COO, Shrinivas Kulkarni as CFO
Shreehas Tambe: Inventor or Co-Inventor on Over 60 patents
As the first CEO & Managing Director of the combined business, Shreehas Tambe will focus on strengthening Biocon’s global leadership in biopharma while addressing critical healthcare needs through an advanced portfolio of biosimilars, insulins, generics, and peptide-based therapies, including GLP–1s.
Shreehas Tambe holds a master’s degree in Bioprocess Technology from ICT (UDCT), University of Mumbai, and has received multiple industry recognitions.
He has also represented India’s biopharmaceutical sector at global forums and worked closely with policymakers on key initiatives such as Production Linked Incentive (PLI) and Promotion of Research and Innovation in Pharma MedTech Sector (PRIP).
